Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL32677064 | 0.98 | EGLN1 (0.42) | EGLN1GRIA2GAAMAPTOPRM1 | |
| Hydrochloric Acid SCHEMBL32676860 | 0.98 | EGLN1 (0.42) | EGLN1GRIA2GAAMAPTOPRM1 | |
| Hydrochloric Acid SCHEMBL14061298 | 0.98 | EGLN1 (0.42) | EGLN1GRIA2GAAMAPTOPRM1 | |
| Hydrochloric Acid SCHEMBL32677144 | 0.98 | EGLN1 (0.42) | EGLN1GRIA2GAAMAPTOPRM1 | |
| SCHEMBL32676976 | 0.86 | SCN3A (0.39) | GAAMAPTOPRM1OPRD1OPRK1 | |
| SCHEMBL32676981 | 0.86 | SCN3A (0.39) | GAAMAPTOPRM1OPRD1OPRK1 | |
| SCHEMBL32676671 | 0.86 | SCN3A (0.39) | GAAMAPTOPRM1OPRD1OPRK1 | |
| SCHEMBL32677208 | 0.84 | KDM4E (0.53) | GAAMAPTOPRM1OPRD1OPRK1 | |
| SCHEMBL32676819 | 0.84 | KDM4E (0.53) | GAAMAPTOPRM1OPRD1OPRK1 | |
| SCHEMBL32677091 | 0.84 | KDM4E (0.53) | GAAMAPTOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612089-B2 | Tetrahydroisoquinolines as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20060160840-A1 | N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006055951-A2 | TETRAHYDROISOQUINOLINES AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160840-A1 | N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample | TFPI, F2, TFPI2 | EGLN1 256/4885GRIA2 4417/4885GAA 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.